Vertex Acquires Crinetics for $10B to Expand into Endocrinology

The deal gives Vertex access to a commercial acromegaly therapy and a late-stage rare disease pipeline as the company diversifies beyond cystic fibrosis.

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately $10 billion, marking the company’s largest acquisition to date.

Under the terms of the agreement, Vertex will acquire Crinetics for $85 per share, with the transaction expected to close in the third quarter of 2026.

The acquisition strengthens Vertex’s position in rare diseases by adding an established endocrinology portfolio, including Palsonify (paltusotine), an oral therapy approved in the US and EU for adults with acromegaly.

Expanding Beyond Cystic Fibrosis

Vertex built its commercial success around cystic fibrosis, with its franchise generating more than $11 billion in revenue in 2025.

The company has used that financial strength to expand into additional therapeutic areas, including gene therapy, pain management and kidney disease.

However, some newer growth areas have faced challenges.

The company’s non-opioid pain medicine Journavx (suzetrigine) gained approval as the first new non-opioid pain treatment in more than two decades. Still, expectations for broader chronic pain adoption have remained limited.

Meanwhile, uptake of Vertex’s gene therapy, Casgevy (exagamglogene autotemcel), has been affected by challenges common to cell and gene therapies, including high costs, reimbursement barriers, and complex treatment pathways.

The Crinetics acquisition provides Vertex with a commercial product and a pipeline focused on rare endocrine disorders.

Palsonify Provides Immediate Commercial Opportunity

The centrepiece of the deal is Palsonify (paltusotine), an oral non-peptide somatostatin receptor type 2 (SST2) agonist designed to treat acromegaly.

The therapy was approved in the US and EU as a first-line treatment for adults with acromegaly, a rare hormonal disorder caused by excess growth hormone production.

Since launching in the US in late 2025, Palsonify has generated approximately $15.7 million in net product revenue.

Vertex said early performance reflects strong demand, expanding prescribing activity and increasing reimbursement coverage.

Vertex CEO Reshma Kewalramani said the company’s experience commercialising rare disease medicines would help accelerate the drug’s growth following the acquisition.

Building a Rare Endocrinology Pipeline

Beyond Palsonify, the acquisition adds Crinetics’ clinical pipeline, led by atumelnant, an oral adrenocorticotropic hormone (ACTH) receptor antagonist currently being studied in Phase III trials for congenital adrenal hyperplasia (CAH).

CAH is a rare genetic disorder characterised by impaired cortisol production and excess androgen levels.

In Phase II studies, atumelnant demonstrated reductions in androgen biomarkers, including androstenedione and 17-hydroxyprogesterone, while allowing patients to maintain physiologic glucocorticoid replacement therapy.

The candidate is also being evaluated in Cushing’s syndrome, another rare endocrine condition.

Crinetics’ wider pipeline includes:

• CRN09682, a Phase I/II programme for neuroendocrine tumours

• Preclinical programmes targeting Graves’ disease

• Thyroid eye disease

• Polycystic kidney disease

• Obesity

• Diabetes
  

Vertex expects Palsonify and atumelnant together could generate peak annual revenue exceeding $5 billion.

Strengthening Vertex’s M&A Strategy

The Crinetics acquisition follows Vertex’s previous major acquisition of Alpine Immune Sciences for $4.9 billion in 2024, which provided the company with povetacicept.

Povetacicept, a dual APRIL/BAFF inhibitor, is currently under FDA review for immunoglobulin A nephropathy (IgAN).

Vertex has previously highlighted renal disease as a potential future growth driver, with the company suggesting its kidney portfolio could eventually surpass its cystic fibrosis business.

Why the Deal Matters

The acquisition highlights several important trends across the biopharmaceutical sector:

• Large pharmaceutical companies continue to use M&A to secure late-stage and commercial assets.

• Rare diseases remain a major focus for pipeline diversification.

• Oral therapies are attracting interest as alternatives to injectable treatments.

• Endocrinology is becoming an increasingly attractive market due to significant unmet medical needs.
  

Summary

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, gaining access to Palsonify and a broader endocrinology pipeline.

The deal strengthens Vertex’s strategy of expanding beyond cystic fibrosis while adding commercial and late-stage rare disease assets across acromegaly, congenital adrenal hyperplasia and other endocrine disorders.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com